TY - JOUR
T1 - Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)
AU - TEMD Study Grp
AU - Sonmez, Alper
AU - Haymana, Cem
AU - Bayram, Fahri
AU - Salman, Serpil
AU - Dizdar, Oguzhan Sitki
AU - Gurkan, Eren
AU - Carlioglu, Ayse Kargili
AU - Barcin, Cem
AU - Sabuncu, Tevfik
AU - Satman, Ilhan
AU - Guldiken, Sibel
AU - Ayturk, Semra
AU - Yilmaz, Murat
AU - Asik, Mehmet
AU - Dinccag, Nevin
AU - Cakmak, Ramazan
AU - Turker, Fulya
AU - Idiz, Cemile
AU - Hacisahinogullari, Hulya
AU - Bagdemir, Elif
AU - Yildiz, Busra
AU - Yumuk, Volkan Demirhan
AU - Haliloglu, Ozlem
AU - Sancak, Seda
AU - Ozsari, Levent
AU - Cagiltay, Eylem
AU - Deyneli, Oguzhan
AU - Imre, Eren
AU - Gonen, Sait
AU - Boysan, S. Nur
AU - Altuntas, Yuksel
AU - Ozturk, Feyza Yener
AU - Mert, Meral
AU - Piskinpasa, Hamide
AU - Aydin, Hasan
AU - Imamoglu, Sazi
AU - Ersoy, Canan
AU - Ozgul, Ozen
AU - Kucuksarac Kiyici, Sinem
AU - Cetinarslan, Berrin
AU - Selek, Alev
AU - Dogru, Teoman
AU - Kirik, Ali
AU - Kebapci, Nur
AU - Efe, Belgin
AU - Kaya, Ahmet
AU - Cordan, Ilker
AU - Baldane, Suleyman
AU - Yildiz, Okan Bulent
AU - Sendur, Suleyman Nahit
PY - 2018/12
Y1 - 2018/12
N2 - Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus.Methods: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c <7%, home arterial blood pressure (ABP) <135/85 mmHg, or LDL-C <100 mg/dL. Achieving all parameters indicated triple metabolic control.Results: HbA1c levels of patients (n = 5211) were 8.6 +/- 1.9% (71 +/- 22 mmol/mol) and 7.7 +/- 1.7% (61 +/- 19 mmol/mol), in Type 1 and Type 2 diabetes, respectively. Glycemic control was achieved in 15.3% and 40.2%, and triple metabolic control was achieved in 5.5% and 10.1%, respectively. Only 1.5% of patients met all the criteria of being non-obese, nonsmoker, exercising, and under triple metabolic control. Low education level was a significant predictor of poor glycemic control in both groups.Conclusions: Few patients with Type 2, and even fewer with Type 1 diabetes have optimal metabolic control in Turkey. TEMD study will provide evidence-based information to policy makers to focus more on the quality and sustainability of diabetes care in order to reduce the national burden of the disease. (C) 2018 Elsevier B.V. All rights reserved.
AB - Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus.Methods: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c <7%, home arterial blood pressure (ABP) <135/85 mmHg, or LDL-C <100 mg/dL. Achieving all parameters indicated triple metabolic control.Results: HbA1c levels of patients (n = 5211) were 8.6 +/- 1.9% (71 +/- 22 mmol/mol) and 7.7 +/- 1.7% (61 +/- 19 mmol/mol), in Type 1 and Type 2 diabetes, respectively. Glycemic control was achieved in 15.3% and 40.2%, and triple metabolic control was achieved in 5.5% and 10.1%, respectively. Only 1.5% of patients met all the criteria of being non-obese, nonsmoker, exercising, and under triple metabolic control. Low education level was a significant predictor of poor glycemic control in both groups.Conclusions: Few patients with Type 2, and even fewer with Type 1 diabetes have optimal metabolic control in Turkey. TEMD study will provide evidence-based information to policy makers to focus more on the quality and sustainability of diabetes care in order to reduce the national burden of the disease. (C) 2018 Elsevier B.V. All rights reserved.
KW - Arterial blood pressure
KW - HbA1c
KW - LDL-cholesterol
KW - Type 1 diabetes
KW - Type 2 diabetes
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000452704800016&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.diabres.2018.09.010
DO - 10.1016/j.diabres.2018.09.010
M3 - Article
C2 - 30244051
SN - 0168-8227
VL - 146
SP - 138
EP - 147
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
ER -